
---
title: '新的研究发现了所有癌症的共同点'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7e76b844-cad1-40e6-8d92-daf61af8af04/fx1_lrg.jpg'
author: 科学网
comments: false
date: Sat, 17 Jul 2021 21:22:00 GMT
thumbnail: 'https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7e76b844-cad1-40e6-8d92-daf61af8af04/fx1_lrg.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;">新的研究发现了所有癌症的共同点</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em;"><a href="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7e76b844-cad1-40e6-8d92-daf61af8af04/fx1_lrg.jpg" target="_blank"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7e76b844-cad1-40e6-8d92-daf61af8af04/fx1_lrg.jpg" referrerpolicy="no-referrer"></span></a></p><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "arial black", "avant garde";"><span style="font-size: 18px;"><a href="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7e76b844-cad1-40e6-8d92-daf61af8af04/fx1_lrg.jpg" target="_blank" style="white-space: normal;">Graphical abstract</a></span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "arial black", "avant garde";"><br></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">据</span>Lunenfeld-Tanenbaum<span style="font-size: 18px; font-family: 宋体;">研究所（</span></span><a href="https://www.sinaihealth.ca/news/lunenfeld-tanenbaum-research-institute/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Lunenfeld-Tanenbaum Research Institute</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>7<span style="font-size: 18px; font-family: 宋体;">月</span>16<span style="font-size: 18px; font-family: 宋体;">日提供的消息，新的研究发现了所有癌症的共同点（</span></span><a href="https://medicalxpress.com/news/2021-07-common-denominator-linking-cancers.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">New research finds common denominator linking all cancers</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）。西奈卫生研究院</span>(Sinai Health)<span style="font-size: 18px; font-family: 宋体;">科学家的一项新研究显示，所有癌症仅可分为两类。这项发现可能为治疗最具侵袭性和无法治愈的癌症提供了一种新策略。这项研究成果已经《癌细胞》</span>(<a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" target="_self">Cancer Cell</a>)<span style="font-size: 18px; font-family: 宋体;">杂志上发表——</span></span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Joel D. Pearson" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Joel D. Pearson</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Katherine Huang" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Katherine Huang</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Marek Pacal" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Marek Pacal</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Sean R. McCurdy" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Sean R. McCurdy</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Suying Lu" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Suying Lu</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Arthur Aubry" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Arthur Aubry</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Tao Yu" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Tao Yu</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Kristine M. Wadosky" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Kristine M. Wadosky</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Letian Zhang" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Letian Zhang</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Tao Wang" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Tao Wang</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Alex Gregorieff" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Alex Gregorieff</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Mohammad Ahmad" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Mohammad Ahmad</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Helen Dimaras" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Helen Dimaras</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Ellen Langille" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Ellen Langille</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Susan P.C. Cole" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Susan P.C. Cole</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Philippe P. Monnier" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Philippe P. Monnier</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Benjamin H. Lok" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Benjamin H. Lok</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Ming-Sound Tsao" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Ming-Sound Tsao</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Nagako Akeno" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nagako Akeno</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Daniel Schramek" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Daniel Schramek</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Kathryn A. Wikenheiser-Brokamp" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Kathryn A. Wikenheiser-Brokamp</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Erik S. Knudsen" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Erik S. Knudsen</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Agnieszka K. Witkiewicz" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Agnieszka K. Witkiewicz</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Jeffrey L. Wrana" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Jeffrey L. Wrana</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author David W. Goodrich" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">David W. Goodrich</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" title="Correspondence information about the author Rod Bremner" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Rod Bremner</span></a><span style="font-size: 18px; font-family: "times new roman";">. <a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" target="_self">Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity</a>. Cancer Cell , Published:July 15, 2021 DOI: </span><span style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><a href="https://doi.org/10.1016/j.ccell.2021.06.016" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank">https://doi.org/10.1016/j.ccell.2021.06.016</a></span><span style="font-family: "times new roman"; font-size: 18px;"> </span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">此项新研究中，西奈卫生研究院</span>(Sinai Health)<span style="font-size: 18px; font-family: 宋体;">的</span>Lunenfeld-Tanenbaum<span style="font-size: 18px; font-family: 宋体;">研究所</span>(</span><a href="https://www.sinaihealth.ca/news/lunenfeld-tanenbaum-research-institute/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Lunenfeld-Tanenbaum Research Institute</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">简称</span>LTRI)<span style="font-size: 18px; font-family: 宋体;">的科学家根据一种名为</span>Yes-associated protein(<span style="font-size: 18px; font-family: 宋体;">简称</span>YAP)<span style="font-size: 18px; font-family: 宋体;">的蛋白质的存在与否，将所有癌症分为两类即<span style="font-family: "times new roman"; font-size: 18px;">YAP</span><sup style="font-family: "times new roman"; white-space: normal;">on</sup></span></span><span style="font-family: 宋体; font-size: 18px;">和</span><span style="font-size: 18px; font-family: "times new roman";">YAP</span><sup style="font-family: "times new roman";">off</sup><span style="font-family: 宋体; font-size: 18px;">。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">LTRI<span style="font-size: 18px; font-family: 宋体;">的资深科学家<span style="font-family: 宋体; font-size: 18px;">罗德·布莱姆纳（</span></span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" target="_self">Rod Bremner</a></span><span style="font-family: 宋体; font-size: 18px;">）</span><span style="font-size: 18px; font-family: 宋体;">说，他们已经确定，所有癌症都存在</span><span style="font-family: "times new roman"; font-size: 18px;">YAP</span><span style="font-size: 18px; font-family: 宋体;">开启或关闭，并且每种分类显示出不同的药物敏感性或耐药性。</span><span style="font-family: "times new roman"; font-size: 18px;">YAP</span><span style="font-size: 18px; font-family: 宋体;">在恶性肿瘤的形成中起着重要作用，因为它是</span><span style="font-family: "times new roman"; font-size: 18px;">Hippo</span><span style="font-size: 18px; font-family: 宋体;">信号通路（</span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" target="_blank" style="font-family: "times new roman"; font-size: 18px;">Hippo signaling pathway</a><span style="font-size: 18px; font-family: 宋体;">）的重要调控因子和效应因子。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体; font-size: 18px;">罗德·布莱姆纳</span><span style="font-size: 18px; font-family: 宋体;">说：“</span>YAP<span style="font-size: 18px; font-family: 宋体;">不仅是关闭或打开，而且在任何一种情况下都有相反的促癌或抗癌作用。因此，</span>YAP<span style="font-size: 18px; font-family: 宋体;">开启（</span>YAP<sup>on</sup><span style="font-size: 18px; font-family: 宋体;">）癌症需要</span>YAP<span style="font-size: 18px; font-family: 宋体;">来生长和生存。相反，当我们打开</span>YAP<span style="font-size: 18px; font-family: 宋体;">时，</span>YAP<span style="font-size: 18px; font-family: 宋体;">关闭（</span>YAP<sup>off</sup><span style="font-size: 18px; font-family: 宋体;">）癌症停止生长。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">许多</span>YAP<sup>off</sup><span style="font-size: 18px; font-family: 宋体;">癌症是高度致命的。在他们的新研究中，罗德·布莱姆纳和来自美国纽约州布法罗罗斯威尔公园综合癌症中心（</span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" target="_blank">Roswell Park Comprehensive Cancer Center in Buffalo</a>, NY, USA<span style="font-size: 18px; font-family: 宋体;">）的其他研究人员表明，前列腺癌和肺癌等一些癌症可以从</span>YAP<sup>on</sup><span style="font-size: 18px; font-family: 宋体;">状态跳转到</span>YAP<sup>off</sup><span style="font-size: 18px; font-family: 宋体;">状态，从而抵抗治疗。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">当癌细胞在实验室的培养皿中生长时，它们不是漂浮着就是粘着。研究小组发现，</span>YAP<span style="font-size: 18px; font-family: 宋体;">是细胞浮力的主要调节器，所有漂浮的细胞都是</span>YAP<sup>off</sup><span style="font-size: 18px; font-family: 宋体;">，所有粘着的细胞都是</span>YAP<sup>on</sup><span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">罗德·布莱姆纳解释说，众所周知，粘附行为的变化与耐药性有关，因此他们的发现暗示了</span>YAP<span style="font-size: 18px; font-family: 宋体;">在这个开关的中心。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">LTRI<span style="font-size: 18px; font-family: 宋体;">罗德·布莱姆纳实验室的博士后研究员、联合作者乔尔·皮尔森</span>(Joel Pearson)<span style="font-size: 18px; font-family: 宋体;">说，治疗这些癌症的疗法可能对患者的生存产生深远的影响。乔尔·皮尔森说：“我们发现的这个简单的二进制规则可能揭示了治疗许多类型的癌症的策略，这些癌症要么属于</span>YAP<sup>off</sup><span style="font-size: 18px; font-family: 宋体;">超类，要么属于</span>YAP<sup>on</sup><span style="font-size: 18px; font-family: 宋体;">超类。此外，由于癌症通过跳转状态来逃避治疗，有方法治疗</span>YAP<sup>off</sup><span style="font-size: 18px; font-family: 宋体;">和</span>YAP<sup>on</sup><span style="font-size: 18px; font-family: 宋体;">状态可能成为一种通用的方法来阻止这种癌症转换类型以抵抗药物治疗。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">研究人员希望通过推断这些类型的癌症的共同弱点，有可能开发出新的治疗方法，并改善患者的预后。这项工作主要由加拿大健康研究院</span>(Canadian Institutes of Health Research<span style="font-size: 18px; font-family: 宋体;">简称</span>CIHR)<span style="font-size: 18px; font-family: 宋体;">、癌症研究协会（</span>Cancer Research Society<span style="font-size: 18px; font-family: 宋体;">）和克莱姆比尔基金会（</span>Krembil Foundation<span style="font-size: 18px; font-family: 宋体;">）提供资助。上述介绍仅供参考，欲了解更多信息敬请注意浏览</span></span><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://www.sinaihealth.ca/news/new-sinai-health-research-finds-common-denominator-linking-all-cancers/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" target="_self" style="font-size: 18px; font-family: "arial black", "avant garde"; text-decoration: underline;"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Highlights</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• YAP/TAZ silencing in multiple cancers reflects their tumor suppressor activity</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• Cancers can be parsed into binary YAP<sup>on</sup> and YAP<sup>off</sup> classes</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• Binary transcriptomes drive distinct adhesive, metabolic, genetic, and drug profiles</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• Alternate YAP enhancers explain anti-cancer integrin-αVβ5 program in YAP<sup>off</sup> cancers</span></p><p style="line-height: 2em;"><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00338-X" target="_self" style="font-size: 18px; font-family: "arial black", "avant garde"; text-decoration: underline;"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Summary</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Cancer heterogeneity impacts therapeutic response, driving efforts to discover over-arching rules that supersede variability. Here, we define pan-cancer binary classes based on distinct expression of YAP and YAP-responsive adhesion regulators. Combining informatics with in vivo and in vitro gain- and loss-of-function studies across multiple murine and human tumor types, we show that opposite pro- or anti-cancer YAP activity functionally defines binary YAP<sup>on</sup> or YAP<sup>off</sup> cancer classes that express or silence YAP, respectively. YAP<sup>off</sup> solid cancers are neural/neuroendocrine and frequently RB1−/−, such as retinoblastoma, small cell lung cancer, and neuroendocrine prostate cancer. YAP silencing is intrinsic to the cell of origin, or acquired with lineage switching and drug resistance. The binary cancer groups exhibit distinct YAP-dependent adhesive behavior and pharmaceutical vulnerabilities, underscoring clinical relevance. Mechanistically, distinct YAP/TEAD enhancers in YAP<sup>off</sup> or YAP<sup>on</sup> cancers deploy anti-cancer integrin or pro-cancer proliferative programs, respectively. YAP is thus pivotal across cancer, but in opposite ways, with therapeutic implications.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1295903.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1295903.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1295901.html" target="_black">[转载]在毕达哥拉斯学派关于√2不是有理数的证明中隐藏着一个“复杂问语”的谬误</a><br>                    <!--大赛结束-->
                                        
  
</div>
            